Pharmacy Benefit Management

FDA Approves Long-Awaited Oral MS Drug; Tecfidera May Have Huge Impact on Class (Table: Most Common NDC at Usual Dose Within Prime’s Commercial Book of Business)FDA Approves Long-Awaited Oral MS Drug; Tecfidera May Have Huge Impact on Class (Table: Most Common NDC at Usual…

From Specialty Pharmacy News - In late March the FDA approved the much-anticipated oral multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate). Known as BG-12 as it was undergoing clinical trials, the Biogen Idec therapy has been hailed as a potential blockbuster by industry insiders and analysts. However, it may be a bit of time before plans will make formulary decisions on the drug beyond a basic prior authorization as they wait to see what the real-world data look like. Read more

AISHealth Access Options

Please select an option below to proceed

Nutrition Support Serves Key Role in Home Infusion TherapyNutrition Support Serves Key Role in Home Infusion Therapy

From Specialty Pharmacy News - In many care situations, home infusion may be the best treatment option for both health plans and their members. And when companies offer this care, it’s important that provider teams include a dietitian who is involved in the management of each patient. A recent Walgreens Infusion Services study involving 2,500 people receiving enteral nutrition (EN) — meaning they are receiving nutrition through a feeding tube — and 270 receiving parenteral nutrition… Read more

AISHealth Access Options

Please select an option below to proceed

More Pharmacy Benefit Management Stories

Pharmacy Benefit Management Blog

amaas's picture
Spending on Drugs, Use of Health Care Services Fell Last Year … But Is That a Good Thing?
By Angela Maas - May 17, 2013
2012 saw some tremendous advances in drug development, notes a recently released study by the IMS Institute for Healthcare Informatics. At the same time, spending on drugs and the utilization of health care services declined nationwide. Released this month, Declining Medicine Use and Costs: For...
lkelly's picture
Obesity Drugs: More Than Just a Lifestyle Category?
By Lauren Flynn Kelly - April 25, 2013
For the latest issue of Drug Benefit News, I revisit the obesity drug category in light of several developments that recently came to my attention. One is that Qsymia (phentermine and topiramate extended-release), which was approved in July 2012 and launched in September, just became available on a...
amaas's picture
Closing the Gap Between Pharmacy Services Valued and What Actually Are Provided
By Angela Maas - April 19, 2013
Patient adherence to medication is one of the top concerns in the health care system today. And when it comes to expensive specialty drugs that often treat potentially deadly conditions, adherence is vital to not only patient outcomes but also cost-effective care. Indeed, according to the pharmacy...
Read more Pharmacy Benefit Management blogs

It's quick and easy to sign up for FREE access to AISHealth.com!

Why do I need to register?